Florida Cancer Specialists & Research Institute (FCS) was recently profiled by TrialSite News and included in the Site Watch Leading category. They have built not only a nationally ranked cancer practice but also a formidable research operation. Recently, they named Shekeab Jauhari, MD, as principal investigator to head Phase I clinical trials at the FCS Drug Development Unit in Lake Mary, Florida, at the Sarah Cannon Research Institute.

The newest unit in the FCS set to open January, 2020—Dr. Jauhari received his medical degree from the University of Miami, Miller School of Medicine and completed his internship and residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. Additionally, he completed his fellowship training at Duke University in Durham, NC, in hematology and oncology.

A Passion for Progress

Manish R. Patel, MD, director of drug development for Sarah Cannon Research Institute at FCS noted about the new lead, “Dr. Jauhari has extensive training in oncology research and shares our passion for expanding access to cutting-edge therapies.” Dr. Patel continued, “I look forward to working with Dr. Jauhari and his team, as our early phase trial unites in Sarasota and Lake Mary will work collaboratively to serve patients who vitally need advanced treatment options.”

FCS & Sarah Cannon Research Institute: A Powerful Combination

The Drug Development Unit, Sarah Cannon Research Institute at FCS is a part of the FCS newest treatment facility. By combining medical oncology services and Phase I clinical trial opportunities for patients with cancer at one strategic location, high quality and high impact clinical research as a care option will be available to those in dire need of options.

One of the Lead Cancer Research Organizations

As TrialSite News profiled, FCS conducts clinical trials at over 36 locations of Sarah Cannon Research Institute, one of the leading clinical research organizations worldwide with a focus on cancer. FCS offers more clinical research options than any private oncology practice in Florida according to their recent press release. They have been recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award. They have touted that a majority of FDA-approved cancer therapies over the last 4 years were evaluated in clinical trials that involved participation from FCS.

With over 230 physicians, 220 advanced practice registered nurses and physician assistants, and around 100 locations in their network, FCS is committed to providing world-class cancer care in the community setting.

Lead Research/Investigator

Shekeab Jauhari, MD 

Call to Action: If you reside in or near Florida and have a cancer diagnosis, you may want to consider an appointment with FCS at least as a second opinion.

Source: Florida Cancer Specialists & Research Institute

Pin It on Pinterest